\n<\/p>\n
Duane Boise CEO stated<\/strong>, “As cannabinoid policy shifts from retail access toward physician directed treatment and insurance participation, companies with IND programs, orphan-drug positioning, and botanical drug pipelines-like MMJ International Holdings-are emerging as the sector’s most strategically aligned opportunities”.<\/strong><\/i><\/p>\n<\/p><\/div>\n Cannabis equities surged this week after the U.S. Food and Drug Administration announced it would exercise enforcement discretion toward certain physician-directed hemp-derived oral CBD products participating in the new Medicare cannabinoid access initiative.<\/p>\n The announcement helped propel the AdvisorShares Pure U.S. Cannabis ETF up 16% for the week<\/strong>, its strongest performance since December, while major operators posted meaningful gains they are unprepared for FDA drug development.<\/p>\n But while markets reacted quickly to the headline, experienced healthcare investors are focusing on a more important development:<\/strong><\/p>\n The federal government is signaling that cannabinoid access will expand – but under a medical framework increasingly shaped by the FDA.<\/strong><\/p>\n That distinction matters.<\/strong><\/p>\n And it explains why MMJ International Holdings<\/strong> may represent one of the most strategically positioned companies in the cannabinoid sector today.<\/p>\n FDA Enforcement Discretion Changes the Investment Landscape<\/strong><\/p>\n FDA Commissioner Dr. Marty Makary confirmed the agency will not enforce certain drug-approval provisions against qualifying oral hemp-derived CBD products participating in the CMS pilot program solely because they contain cannabidiol.<\/a><\/p>\n The policy allows Medicare beneficiaries access to physician-directed CBD supplements within defined safety and labeling boundaries.<\/p>\n This is not legalization.<\/p>\n It is not full regulatory approval.<\/p>\n But it is a signal<\/strong> that the federal government is preparing structured medical access pathways for cannabinoids.<\/p>\n Markets noticed immediately.<\/p>\n Yet most public cannabis companies benefiting from the rally remain primarily:<\/p>\n retail-focused MMJ International Holdings is different.<\/strong><\/p>\n The Sector Is Rallying – But the Regulatory Winners Will Be Pharmaceutical<\/strong><\/p>\n Many investors still misunderstand the difference between:<\/p>\n single-molecule botanical-derived drugs Approximately 20-25% of approved pharmaceuticals originate from plant-derived molecules<\/strong>.<\/p>\n Those drugs can be synthesized once identified.<\/p>\n But botanical drugs are far more complex.<\/strong><\/p>\n They contain:<\/p>\n multi-compound plant extracts Standardizing them requires advanced chemistry, manufacturing, and controls (CMC).<\/p>\n That complexity explains why the FDA has approved only four botanical drugs in modern regulatory history<\/strong>.<\/p>\n MMJ International Holdings is developing one of them.<\/p>\n MMJ Is Already Operating Inside the FDA Drug Development System<\/strong><\/p>\n While most cannabis companies are reacting to policy shifts, MMJ has spent years preparing for them.<\/p>\n Its cannabinoid therapeutics platform includes:<\/p>\n FDA IND clinical program infrastructure This is the pathway institutional healthcare capital follows.<\/p>\n Not dispensary expansion.<\/p>\n Medicare CBD Coverage Strengthens MMJ’s Strategic Position<\/strong><\/p>\n The CMS pilot allowing reimbursement for hemp-derived cannabinoid products represents a structural shift in federal policy.<\/p>\n It confirms three important signals:<\/p>\n the federal government accepts cannabinoid therapeutic potential<\/strong><\/p>\n physician-directed cannabinoid access is expanding<\/strong><\/p>\n insurance linked cannabinoid pathways are emerging<\/strong><\/p>\n But the program also creates a policy contradiction:<\/p>\n supplement-grade cannabinoids can now receive reimbursement That gap increases the relative importance of companies already positioned inside the FDA approval framework.<\/p>\n MMJ is one of them.<\/strong><\/p>\n Why Traditional Cannabis Operators Face Structural Limits<\/strong><\/p>\n Companies like Tilray, Canopy Growth, and Curaleaf benefited from this week’s rally.<\/p>\n However, they remain constrained by:<\/p>\n exchange listing barriers The FDA’s botanical drug pathway represents an entirely different category of value creation.<\/p>\n It produces:<\/p>\n reimbursable medicines<\/strong> That is where long-term capital moves.<\/p>\n The Rare Opportunity Created by Botanical Drug Development<\/strong><\/p>\n Developing an FDA-approved botanical cannabinoid drug is difficult.<\/p>\n That is precisely why it is valuable.<\/p>\n Few companies attempt it.<\/p>\n Fewer succeed.<\/p>\n MMJ International Holdings has already completed major components of the hardest regulatory work:<\/p>\n 1.standardization<\/strong> The company is not reacting to federal policy changes.<\/p>\n It anticipated them.<\/p>\n Statement From CEO Duane Boise<\/strong><\/p>\n “The FDA’s decision to allow physician-directed cannabinoid access through Medicare confirms what we have said for years,” said Duane Boise, CEO of MMJ International Holdings<\/strong>. “Cannabinoids belong inside the medical system. Companies that followed the FDA clinical pathway are positioned to lead the next phase of this industry.”<\/p>\n The Market Is Beginning to Recognize the Difference<\/p>\n This week’s cannabis stock rally reflects excitement.<\/p>\n But regulatory structure determines outcomes.<\/p>\n As cannabinoids move closer to physician-directed access, reimbursement eligibility, and FDA-aligned oversight, companies operating inside the pharmaceutical pathway stand to benefit the most.<\/p>\n MMJ International Holdings is already there.<\/strong><\/p>\n CONTACT:<\/strong>
\n WASHINGTON, April 6, 2026 (Newswire.com)
\n –
\n <\/strong>As cannabis stocks rally following new federal flexibility on hemp derived CBD products, investors are asking a deeper question: <\/strong>which companies are actually positioned to succeed under the emerging FDA led cannabinoid regulatory framework?<\/strong><\/a><\/p>\n
state-regulated
supplement-adjacent
or internationally fragmented operators<\/p>\n
and
FDA botanical drugs<\/p>\n
variable terpene interactions
minor cannabinoid contributions
matrix-dependent pharmacokinetics<\/p>\n
Orphan Drug Designation for Huntington’s disease
standardized botanical soft-gel dosage formulation
DEA Schedule I analytical laboratory authorization
pharmaceutical-grade extract characterization
controlled clinical supply architecture<\/p>\n
while clinical-trial cannabinoid manufacturing remains constrained<\/p>\n
interstate commerce restrictions
state-level regulatory fragmentation
absence of FDA clinical drug pipelines<\/p>\n
insurance coverage eligibility<\/strong>
exclusive indications<\/strong>
orphan-drug protection<\/strong>
pharmaceutical partnerships<\/strong><\/p>\n
2.dose reproducibility<\/strong>
3.extract characterization<\/strong>
4.clinical-trial preparation<\/strong><\/p>\n
Madison Hisey
MHisey@mmjih.com<\/a>
203-231-85832<\/p>\n